Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 4
1998 5
1999 10
2000 7
2001 9
2002 9
2003 10
2004 7
2005 5
2006 3
2007 4
2008 2
2009 1
2010 2
2011 3
2012 1
2013 1
2014 4
2015 2
2016 1
2023 5
2024 6
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 32119263

101 results

Results by year

Filters applied: . Clear all
Page 1
Glycoprotein IIb/IIIa Inhibitors.
Tummala R, Rai MP. Tummala R, et al. 2023 Jul 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Jul 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32119263 Free Books & Documents.
Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and angiographic microvascular obstruction: the REVERSE-FLOW trial.
Eitel I, Saraei R, Jurczyk D, Fach A, Hambrecht R, Wienbergen H, Frerker C, Schmidt T, Allali A, Joost A, Marquetand C, Kurz T, Haaf P, Fahrni G, Mueller C, Desch S, Thiele H, Stiermaier T. Eitel I, et al. Eur Heart J. 2024 Dec 16;45(47):5058-5067. doi: 10.1093/eurheartj/ehae587. Eur Heart J. 2024. PMID: 39217605 Clinical Trial.
Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.
Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, Ziada KM, Brennan DM, Ellis SG, Topol EJ. Roffi M, et al. Circulation. 2002 Dec 10;106(24):3063-7. doi: 10.1161/01.cir.0000041250.89627.a9. Circulation. 2002. PMID: 12473552
Low dose intravenous cangrelor versus glycoprotein IIb/IIIa inhibitors in endovascular treatment of tandem lesions.
Jumaa MA, Rodriguez-Calienes A, Dawod G, Vivanco-Suarez J, Hassan AE, Divani AA, Oliver M, Ribo M, Petersen N, Abraham M, Fifi J, Guerrero WR, Malik AM, Siegler JE, Nguyen T, Sheth S, Yoo A, Linares G, Janjua N, Quispe-Orozco D, Galecio-Castillo M, Zevallos C, Malaga M, Farooqui M, Jovin T, Zaidi S, Ortega-Gutierrez S. Jumaa MA, et al. J Stroke Cerebrovasc Dis. 2023 Dec;32(12):107438. doi: 10.1016/j.jstrokecerebrovasdis.2023.107438. Epub 2023 Oct 24. J Stroke Cerebrovasc Dis. 2023. PMID: 37883826 Free PMC article.
Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I. Ciccone A, et al. Cochrane Database Syst Rev. 2014 Mar 8;(3):CD005208. doi: 10.1002/14651858.CD005208.pub3. Cochrane Database Syst Rev. 2014. PMID: 24609741 Review.
101 results